TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?

Amaç: Toplumda sık görülen tiroid nodüllerinin iyi değerlendirilmesi takip veya cerrahi kararı için önemlidir. Serum kalsitonin(SK) düzeyi aslında medüller tiroid kanseri(MTK) tanısı için duyarlı ve özgül bir yöntemdir. Bu çalışmamızda sitolojisi Bethesda I(tanısal olmayan-TO) ve III(önemi belirsiz atipi-ÖBA) olan hastalarımızda SK ile taramanın değerini irdelemeyi amaçladık.Materyal ve Metot: Kliniğimizde 2007-2018 tarihleri arasında tiroidektomi yapılan hastalar arasından preoperatif SK düzeyi bakılanların sitoloji ve histopatoloji sonuçları retrospektif olarak değerlendirildi.Bulgular: Opere olan 6905 hasta içinde SK değeri olan hasta sayısı 881 idi. Kalsitonin değerleri <2, 2-10 ve >10 pg/mL olarak 3 ayrı grupta (sırasıyla; Grup 1,2 ve 3) sınıflandırıldı. Bu hastaların 217 (%24,63)’si TO, 275(%31,21)’i ÖBA idi. Her iki grupta da cinsiyet dağılımı benzerdi(p=0,700). Tanısal olmayan gruptaki hastaların %84,79’inde kalsitonin düzeyleri 1. , %14,29’unde 2. ve %0,92’u 3. grupta yer alırken, ÖBA’lı hastaların %82,91’i 1. , %15,64’ü 2. ve %1,45’i 3. grupta yer alıyordu(p=0,786). Önemi belirsiz atipi olan hastaların %30’unda histopatolojide malignite saptanırken, TO grubundaki hastaların %11,60’sındasaptandı(p=0,006). Histopatolojide malign saptanan hastalarda SK değerlerinin %82,90’ı 1., %15,38’i 2. ve %1,70’si 3. grupta iken benign saptanan hastalarla kıyaslandığında bu oranlar benzerdi(p=0,160). Çalışmada 2 kadın hastanın SK’i çok yüksekti (144 pg/mL ve 655 pg/mL). İki hastanın da sitolojisi ÖBA ve histopatolojisi maligndi.Sonuç: Özellikle Bethesda III tiroid nodüllerinde tedavi kararı verirken SK düzeyini bilmenin faydalı olabileceğini düşünmekteyiz.

Anahtar Kelime:

IS EVALUATION OF SERUM CALCITONIN LEVELS SIGNIFICANT FOR PATIENTS WITH THYROID NODULES?

Öz:

Objectives: Appropriate assessment of thyroid nodules which are commonly seen in the population is important for giving the decision of follow-up or surgery. In fact, serum calcitonin (SC) level is a sensitive and specific method in the diagnosis of medullary thyroid cancer (MTC). In the present study, we aimed to evaluate the value of screening with SC in patients with cytology of Bethesda I(nondiagnostic-ND) and III (atypia of undetermined significance -AUS). Materials and Methods: The preoperative SC, cytology results, and postoperative histopathology reports of patients who had thyroidectomy between 2007-2018 in our institution were evaluated retrospectively. Results: Of the 6905 thyroidectomized patients, 881 had SC values. Patients were classified as Group 1, 2, and 3 according to SC <2, 2-10 and >10pg/mL; respectively. Of these patients, 217(24.63%) had ND and 275(31.21%) had AUS cytology. The gender distribution was similar between the two groups(p=0.700). However, SC was found as 84.79%, 14.29%, and 0.92% of 1, 2, and 3 groups in patients with ND, it was found as 82.91%, 15.64%, and 1.45% in patients with AUS, respectively(p=0.786). In histopathology, malignancy was detected in 30% of patients with AUS and 11.60% with ND(p=0.006). Calcitonin of patients with malignant histopathology was evaluated in 82.90%, 15.38%, and 1.70% as Group 1, 2, and 3, respectively which was similar compared to patients with benign histopathology(p=0.160). Two female patients had very high SC(144pg/ml and 655pg/mL). Both patients had AUS cytology and malignant histopathologies. Conclusion: We think that the assessment of SC can be useful in the treatment decision of patients especially with Bethesda III nodules.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26(1): 1- 133.
2. Crippa S, Mazzucchelli L, Cibas ES, Ali SZ. The Bethesda System for reporting thyroid fine-needle aspiration specimens. Am J Clin Pathol 2010; 134: 343–4.
3. Cibas ES, Ali SZ. The 2017 Bethesda System for reporting Thyroid Cytopathology. Thyroid 2017; 27(11): 1-6.
4. Degirmenci B, Haktanir A, Albayrak R ve ark. Sonographically guided fine-needle biopsy of thyroid nodules: the effects of nodule characteristics, sampling technique, and needle size on the adequacy of cytological material. Clin Radiol 2007; 62: 798-803.
5. Choi SH, Han KH, Yoon JH, et al. Factors affecting inadequate sampling of ultrasound guided fineneedle aspiration biopsy of thyroid nodules. Clin Endocrinol (Oxf) 2011; 74: 776-82.
6. Moon HJ, Kwak JY, Kim EK, Kim MJ. Ultrasonographic characteristics predictive of nondiagnostic results for fineneedle aspiration biopsies of thyroid nodules. Ultrasound Med Biol 2011; 37: 549-55.
7. Grani G, Calvanese A, Carbotta G, et al. Intrinsic factors affecting adequacy of thyroid nodule fineneedle aspiration cytology. Clin Endocrinol (Oxf) 2013; 78: 141-4.
8. Choi YS, Hong SW, Kwak JY, Moon HJ, Kim EK. Clinical and ultrasonographic findings affecting nondiagnostic results upon the second fine needle aspiration for thyroid nodules. Ann Surg Oncol 2012; 19: 2304-9.
9. Chung J, Youk JH, Kim JA, et al. Initially non-diagnostic ultrasound-guided fine needle aspiration cytology of thyroid nodules: value and management. Acta Radiol 2012; 53: 168-73.
10. Anderson TJ, Atalay MK, Grand DJ, Baird GL, Cronan JJ, Beland MD. Management of nodules with initially nondiagnostic results of thyroid fine-needle aspiration: can we avoid repeat biopsy? Radiology 2014; 272: 777-84.
11. Straccia P, Rossi ED, Bizzarro T, et al. A meta-analytic of review of the Bethesda System for Reporting Thyroid Cytopathology: Has the rate of malignancy in indeterminate lesions has been underestimated?. Cancer Cytopathol 2015; 123: 713-22.
12. Ahmed S, Ahmad M, Khan MA, et al. The interobserver reproducibility of thyroid cytopthology using Bethesda reporting system: analysis of 200 cases. J Pak Med Assoc 2013; 63: 1252-5. 13. Faquin WC, BAloch ZW. Fine-needle aspiration of follicular patterned patterned lesions of the thyroid: diagnosis, management, and follow-up according to National Cancer Institude (NCI) recommendations. Diagn Cytopathol 2010; 38: 731-9.
14. Pacini F, Castagna MG, Brilli L, Pentheroudakis G, ESMO Guidelines Working Group. Thyroid cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(suppl 7):vii, 110–9.
15. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25: 567–610.
16. Chang TC, Wu SL, Hsiao YL. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations. Acta Cytol 2005; 49:477–82.
17. Trimboli P, Treglia G, Guidobaldi L, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol (Oxf) 2015; 82: 280–5.
18. Tuttle RM, Ball DW, Byrd D, et al. National Comprehensive Cancer Network. Medullary carcinoma. J Natl Compr Canc Netw 2010; 8: 512–30.
19. Valenta LJ, Michel-Bechet M, Mattson JC, Singer FR. Microfollicular thyroid carcinoma with amyloid rich stroma resembling the medullary carcinoma of the thyroid (MCT). Cancer 1977; 39:1573–86.
20. Papaparaskeva K, Nagel H, Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagn Cytopathol 2000; 22: 351–8.
21. Trimboli P, Cremonini N, Ceriani L, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. Clin Endocrinol 2014; 80: 135–40.
22. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89: 163–8.
23. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997; 82: 1589–93.
24. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007; 92: 450–5. , 25. Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab 2008; 93: 2173–80.
26. Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid 2011; 21: 1199–207.

APA	Aydın C, topaloglu o, evranos ogmen b, Bestepe N, Ulusoy S, aksoy altinboga a, Ersoy R, Cakir B (2020). TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?. , 605 - 614. 10.5505/amj.2020.25991
Chicago	Aydın Cevdet,topaloglu oya,evranos ogmen berna,Bestepe Nagihan,Ulusoy Serap,aksoy altinboga aysegul,Ersoy Reyhan,Cakir Bekir TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?. (2020): 605 - 614. 10.5505/amj.2020.25991
MLA	Aydın Cevdet,topaloglu oya,evranos ogmen berna,Bestepe Nagihan,Ulusoy Serap,aksoy altinboga aysegul,Ersoy Reyhan,Cakir Bekir TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?. , 2020, ss.605 - 614. 10.5505/amj.2020.25991
AMA	Aydın C,topaloglu o,evranos ogmen b,Bestepe N,Ulusoy S,aksoy altinboga a,Ersoy R,Cakir B TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?. . 2020; 605 - 614. 10.5505/amj.2020.25991
Vancouver	Aydın C,topaloglu o,evranos ogmen b,Bestepe N,Ulusoy S,aksoy altinboga a,Ersoy R,Cakir B TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?. . 2020; 605 - 614. 10.5505/amj.2020.25991
IEEE	Aydın C,topaloglu o,evranos ogmen b,Bestepe N,Ulusoy S,aksoy altinboga a,Ersoy R,Cakir B "TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?." , ss.605 - 614, 2020. 10.5505/amj.2020.25991
ISNAD	Aydın, Cevdet vd. "TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?". (2020), 605-614. https://doi.org/10.5505/amj.2020.25991

APA	Aydın C, topaloglu o, evranos ogmen b, Bestepe N, Ulusoy S, aksoy altinboga a, Ersoy R, Cakir B (2020). TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?. Ankara Medical Journal, 20(3), 605 - 614. 10.5505/amj.2020.25991
Chicago	Aydın Cevdet,topaloglu oya,evranos ogmen berna,Bestepe Nagihan,Ulusoy Serap,aksoy altinboga aysegul,Ersoy Reyhan,Cakir Bekir TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?. Ankara Medical Journal 20, no.3 (2020): 605 - 614. 10.5505/amj.2020.25991
MLA	Aydın Cevdet,topaloglu oya,evranos ogmen berna,Bestepe Nagihan,Ulusoy Serap,aksoy altinboga aysegul,Ersoy Reyhan,Cakir Bekir TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?. Ankara Medical Journal, vol.20, no.3, 2020, ss.605 - 614. 10.5505/amj.2020.25991
AMA	Aydın C,topaloglu o,evranos ogmen b,Bestepe N,Ulusoy S,aksoy altinboga a,Ersoy R,Cakir B TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?. Ankara Medical Journal. 2020; 20(3): 605 - 614. 10.5505/amj.2020.25991
Vancouver	Aydın C,topaloglu o,evranos ogmen b,Bestepe N,Ulusoy S,aksoy altinboga a,Ersoy R,Cakir B TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?. Ankara Medical Journal. 2020; 20(3): 605 - 614. 10.5505/amj.2020.25991
IEEE	Aydın C,topaloglu o,evranos ogmen b,Bestepe N,Ulusoy S,aksoy altinboga a,Ersoy R,Cakir B "TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?." Ankara Medical Journal, 20, ss.605 - 614, 2020. 10.5505/amj.2020.25991
ISNAD	Aydın, Cevdet vd. "TİROİD NODÜLÜ OLAN HASTALARDA SERUM KALSİTONİN DÜZEYLERİ BAKMAK ANLAMLI MIDIR?". Ankara Medical Journal 20/3 (2020), 605-614. https://doi.org/10.5505/amj.2020.25991